Entrada Therapeutics, Inc. beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses), averaging +17.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.16 | $-1.01 | +12.9% | Beat | |
| Q1 FY26 | $-1.06 | $-0.95 | +10.4% | Beat | |
| Q4 FY25 | $-1.32 | $-0.94 | +28.8% | Beat |
Back to TRDA overview · TRDA holders · TRDA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.